American Capital Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

American Capital Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5K	Sell	4 -1	-20%	-$681	﹤0.01%	573
2026 Q1	$3.86K	Buy	5 +2	+67%	+$1.53K	﹤0.01%	428
2025 Q4	$2.32K	Buy	3 +1	+50%	+$679	﹤0.01%	445
2025 Q3	$1.13K	Hold	2	–	–	﹤0.01%	520
2025 Q2	$1.05K	Buy	2 +1	+100%	+$558	﹤0.01%	488
2025 Q1	$635	Buy	+1	New	+$688	﹤0.01%	480

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

American Capital Advisory's REGN Position: Q2 2026 in Review

American Capital Advisory reduced its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, selling an estimated $681 and leaving 4 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #573.

American Capital Advisory first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.86K in Q1 2026. 753 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

American Capital Advisory held 4 shares of Regeneron Pharmaceuticals worth $2.5K as of Q2 2026.
American Capital Advisory sold 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
Regeneron Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #573 holding.
American Capital Advisory first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
American Capital Advisory's Regeneron Pharmaceuticals position peaked at $3.86K in Q1 2026.
753 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.